25 / 30
PHASE III TRIALS COMPARISON: POPULATION
Cabozantinib
(n=470 )
Regorafenib
(n=237)
Ramucirumab*
(n=197)
Median age, years
64
64
64
Male, %
81
85
78
AFP>400 ng/ml, %
41
43
100
ECOG 0/1
52 / 48
55 / 45
57 / 43
Etiology of HCC
HBV
38
38
36
HCV
22
22
24
Other
40
41
40
Extrahepatic Spread, %
79
77
72
Macrovascular Invasion, %
27
34
36
* REACH 2 Trial data only